From Evidence to Optimal Management: Focus on the Results and Implications of Landmark Clinical Trials - Evaluating the Safety and Efficacy of Interleukin- Targeted Therapies in Patients with Moderate-to- Severe Atopic Dermatitis - The Rationale, Evidence, and Emerging Role for Biologic- Based Treatments, Including Monoclonal Antibodies in AP: The Translational Implications of Interleukin-Targeted Therapies for AD - Prof. Andreas Wollenberg, MD